Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Cell Therapy vs Aldesleukin in Metastatic Melanoma
NCT01118091Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2010
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GC101 TIL + pembrolizumab in melanoma, sponsored by National Cancer Institute. Started Apr 2010; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01118091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01118091.